Liquidia Corp (LQDA) · Nov 18, 2026 · Exec change

Liquidia executive change adds strategy role as YUTREPIA resets

CSO appointment

Liquidia’s executive change expands Russell Schundler’s role to strategy as YUTREPIA navigates a narrower commercial opportunity.

Liquidia is a commercial-stage biotech now centered on YUTREPIA, while a recent settlement narrowed the product’s label to pulmonary arterial hypertension and left the company with substantial settlement payments. The filing adds strategic bandwidth, but not a new strategy. Russell Schundler, already Liquidia’s general counsel since March 2021, is being given the additional Chief Strategy Officer title effective November 16, 2026. 〔0〕 〔1〕 That continuity matters as Liquidia manages the YUTREPIA relaunch after the legal settlement, but the 8-K gives no strategic priorities, transaction, commercial target, or operational change to justify treating this as a business inflection.

The compensation package reinforces the importance of the role, while adding cost and dilution. His base salary rises to $625,000, his target bonus to 60%, and he receives $500,000 of time-vested RSUs. The package is meaningful, but its business value depends on what strategy Schundler actually implements; this filing does not provide that evidence.

Bottom line: This is a modest organizational signal, not a change to Liquidia’s operating story. It slightly strengthens continuity during a complicated YUTREPIA transition, but leaves the core strategy—and its results—undisclosed.

Original filing on SEC EDGAR

More Liquidia Corp news

Liquidia executive change adds strategy role as YUTREPIA resets | LQDA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.